Introduction {#Sec1}
============

Aniridia (MIM:106210) is a rare, bilateral, congenital ocular disorder causing incomplete formation of the iris. The visual impairment caused by iris aplasia/hypoplasia might be enhanced by several ocular anomalies, such as cataracts, glaucoma, corneal pannus, macular hypoplasia, nystagmus, and photophobia. The prevalence of aniridia in the general population is approximately 1 in 64,000 to 1 in 96,000 live births. Two-thirds of cases are familial, with autosomal dominant mode of inheritance, complete penetrance, and variable expressivity. One-third of cases are sporadic and result from *de novo* mutations (Kokotas and Petersen [@CR9]).

Mutations in the *PAX6* gene {#Sec2}
----------------------------

*PAX6* (MIM:607108; NM_001604.4) was identified as a candidate gene for aniridia by positional cloning in 1991 (Ton et al. [@CR14]). Mutations in the *PAX6* gene are the major cause of congenital aniridia. *PAX6* is a member of the paired box gene family, located on chromosome 11p13, and consists of 14 exons that span over 22 kb in length. It encodes a 422-amino acid transcriptional factor, involved in oculogenesis and other developmental processes. The protein contains three functional domains: paired domain (PD) and homeodomain (HD), separated by the proline/serine/threonine-rich transactivation domain (PST). The paired domain comprises two structurally distinct DNA-binding subdomains: the N-terminal subdomain (NTS) and the C-terminal subdomain (CTS) (Kokotas and Petersen [@CR9]). The protein is abundantly expressed in the forebrain, early eye structures, ventral spinal cord, and endocrine pancreas (Lauderdale et al. [@CR10]). Pathogenic alterations in the *PAX6* gene reported to date include: nonsense, splicing, frame-shifting insertions or deletions, in-frame insertions or deletions, missense, and run-on mutations (D'Elia et al. [@CR3]). Human *PAX6* mutations are archived in the *PAX6* Allelic Variant Database (LOVD: Leiden Open Variation Database, <http://lsdb.hgu.mrc.ac.uk/home.php>). The majority of mutations in the *PAX6* gene are nonsense mutations, which are considered to produce truncated transcripts that activate the nonsense-mediated decay (NMD) process, resulting in haploinsufficiency of *PAX6* (Fantes et al. [@CR4]).

11p13 deletions {#Sec3}
---------------

Aniridia can be also caused by chromosomal rearrangements that involve the 11p13 region. A significant proportion of chromosomal rearrangements are submicroscopic microdeletions (Crolla and van Heyningen [@CR1]). There have been described cases of aniridia with deletions not involving the structure of the gene but with the removal of 3' regulatory elements essential for adequate *PAX6* expression and known as a "position effect" (Fantes et al. [@CR4]).

Chromosomal alterations in the chromosome 11p, encompassing the *PAX6* and *WT1* (\*607102) genes, may cause WAGR syndrome (MIM:194072). WAGR syndrome is a rare contiguous gene deletion syndrome, clinically associated with Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (Fischbach et al. [@CR6]). Wilms' tumor is one of the most common solid tumors of childhood, which affects approximately 1 in 10,000 children. In patients with WAGR syndrome, the risk that Wilms' tumor will develop reaches 45 % (Crolla and van Heyningen [@CR1]).

The aim of this study was to analyze the genetic background of disease in Polish patients with aniridia.

Materials and methods {#Sec4}
=====================

Patients {#Sec5}
--------

This study comprises 12 unrelated patients of Polish origin, with a clinical diagnosis of aniridia, based on ophthalmologic examination and family history. Among them, there are five patients with positive family history, six sporadic cases, and one patient (p6) who was adopted, for whom we have no information about the patient's biological parents. The ophthalmologic findings of the patients are summarized and compared in Table [1](#Tab1){ref-type="table"}. The local ethics committee approved the study and a written informed consent was obtained from all subjects or their legal guardians.Table 1Clinical features of the patientsPatientAniridiaCongenital cataractCongenital glaucomaNystagmusPhotophobiaOther featuresp1+++++−p2++−−−Complex microphthalmia, lens subluxationp3+−+−−Atrophy of the eyeballs, blindnessp4++−++Atrophy of the optic nerves, persistent hyaloid arteryp5+ (partial)+−++Atrophy of the optic nerves, psychomotor developmental delayp6+−−++Facial dysmorphy, left kidney agenesisp7++−+−−p8+−−+−Astigmatismp9++−++−p10+ (partial)+−−−Lens subluxation, macular hypoplasiap11+−−+−Psychomotor developmental delay, muscular hypotony, cryptorchidism (WAGR syndrome)p12+++++Atrophy of the eyeballs, uveal coloboma

Methods {#Sec6}
-------

Genomic DNA was extracted from venous blood samples using a standard salting-out procedure. Patients were screened for structural rearrangements in the 11p13 region, using multiplex ligation probe amplification (MLPA) analysis. MLPA allowed in the first instance to exclude *WT1* gene deletion, associated with a high risk of Wilms' tumor. MLPA reaction was performed using the P219-B1 commercial kit (MRC-Holland, Amsterdam, Netherlands), following the manufacturer's instructions and using an exactly defined amount of genomic DNA (200 ng). The kit contains probes for the *PAX6* gene (with the exception of exon 6) and for the following genes located upstream, *WT1*, *HIPK3*, *LMO2*, *EHF*, *CD44*, and *RCN1*, and downstream, *BDNF*, *FSHB*, *DCDC1*, and *ELP4*, of *PAX6*. Data were intra-normalized by dividing the area of the peak for each amplification product by the total area of the reference probes' products in the probemix. Inter-sample normalization was achieved by dividing the intra-normalized probe ratio of all reference samples. Data normalization was performed within one experiment (MRC-Holland). Peak areas in the range 0.65--1.31 were considered normal, below 0.65 as a deletion, and above 1.31 as a duplication. Each MLPA analysis included several control samples (DNA from healthy individuals).

The coding regions of the *PAX6* gene were sequenced (exon 5a included) to exclude point mutations. PCR products were separated on an ABI 3130xl Capillary Sequencer (Applied Biosystems). Additionally, in patients p2, p3, and p6, the *PAX6* gene promoter was sequenced. The sequenced fragment included 5′UTR and 1,500 nucleotides upstream of the 5′UTR fragment of the *PAX6* gene. The sequences of the primers used in the amplification and sequencing of the *PAX6* gene and *PAX6* promoter are given in Table [2](#Tab2){ref-type="table"}. Subsequently, to uncover probable, smaller, rare copy number variations (CNVs), array comparative genomic hybridization analysis (using NimbleGen Human CGH 6x630K, Roche) of these three patients was performed. The DNA labeling reaction and hybridization were carried out according to the manufacturer's instructions.Table 2Primers used for the amplification and sequencing of the *PAX6* gene and *PAX6* gene promoter*PAX6* geneExonSense primerAntisense primerProduct size (bp)4AACAGAGCCCCATATTCGAGGAGTCCCTGTGTCCTCCCC1435CTCTTCTTCCTCACTCTGCGAAATGAAGAGAGGGCGTTG2685aCTCTACAGTAAGTTCTCATACCGGAAGTGGACAGAAAACCAC1976--7TTTGATGCATCTTCAGGCAGGACTCCCCACACTTGACTCC7488TGGGTGACTGTGTCTTCAGGAATGGTTGGGAGAGTAGGGG3009TTAAGACTACACCAGGCCCCTGAAGATGTGGCATTTACTTTG29410--11TTGATGCACAGTTTGGTCAACGTGAGAGTCAGAGCCCGGAG60212TAAACCTGTTTGCTCCGGGAAGCTCTCAAGGGTGCAGAC28213CTTGTTGGCAGAGTTCCTCGAGGAGTTAAACACGCCCTCC34714CCATGTCTGTTTCTCAAAGGGAAGCTCAACTGTTGTGTCCC222*PAX6* gene promoter  product 1AAGAGTCTAGCGTACCCTTCGCTGACCACACACCAGAAGTC288  product 2TGGACTTCTGGTGTGTGGTCGGTATGTCAGCGTGTGTCGT185  product 3CACGCTGACATACCGACATCAAGCCAGGGGAGATAAGAGG156  product 4AGAGAATCCCTCCCAGCATTTCCTCACCAAACACTCACCA163  product 5CAGCCGCACTTAGTCAACAACGCCCTTTCTTCTCTCCTTT195  product 6GCTTCCGAAAGGAGAAAGGACCCCTTGGAAGAAGAGGAAA216  product 7CCCCTTTCCTCTTCTTCCAACAATTGGTCCGTTTGTTTGA386  product 8ACCCAGAAACCTTCACTTGACAGCAAAACACTTCCTCCTGC416

Results {#Sec7}
=======

MLPA examination revealed different size heterozygous deletions of the 11p13 region in five patients. In three cases, deletions encompassed the *PAX6* gene and a few adjacent genes. The heterozygous deletion in patient p8 contains five annotated genes: *PAX6*, doublecortin domain-containing protein 1 (*DCDC1*, MIM:608062), elongation factor protein 4 (*ELP4*, MIM:606985), brain-derived neurotrophic factor (*BDNF*, MIM:113505), and beta polypeptide of follicle-stimulating hormone (*FSHB*, MIM:136530) (Fig. [1](#Fig1){ref-type="fig"}a). The heterozygous deletion in patient p9 harbors the following six genes: *PAX6*, *DCDC1*, *ELP4*, *FSHB*, reticulocalbin 1 (*RCN1*, MIM:602735), and *DKFZp686K1684*. In patient p11, a large heterozygous deletion of the 11p13 region (*WT1* gene included) was found (Fig. [1](#Fig1){ref-type="fig"}b), which confirmed the diagnosis of WAGR syndrome. In one patient (p12), a heterozygous deletion of several contiguous exons (exons 1--8) of the *PAX6* gene was found (Fig.[1](#Fig1){ref-type="fig"}c). In patient p10, MLPA revealed a heterozygous deletion of approximately 0.6 Mb on chromosome 11. The deletion did not include the *PAX6* sequence. The following four genes located downstream of *PAX6* are present in the deleted region: *DCDC1*, zinc finger CLS domain containing protein 3 (*DPH4*, MIM:611072), IMP1 inner mitochondrial membrane peptidase (*IMMP1L*, MIM:612323), and *ELP4* (published data, Wawrocka et al. [@CR15]).Fig. 1The normalized multiplex ligation probe amplification (MLPA) results of the three probands. *A* patient p8, *B* patient p11, *C* patient p12. The *light gray columns* represent the deleted probes

The analysis of the coding region of the *PAX6* gene by direct sequencing revealed three different point mutations in the remaining four patients. All the detected mutations were previously reported. In patient p1, we identified a c.718C \> T heterozygous nonsense mutation, which occurred in the protein homeodomain (HD), resulting in a change of arginine to stop codon (p.Arg240\*). In patients p4 and p7, another heterozygous nonsense mutation at position c.949C \> T was identified. It is present in the PST domain coding region, and results in a premature termination of the PAX6 protein (p.Arg317\*). According to the database, the identified mutations are common deleterious mutations in the *PAX6* gene and they probably encode a non-functional protein. Bidirectional sequencing of exon/intron boundaries for patient p5 resulted in the identification of a nucleotide substitution at the splice donor sequence of intron 6, c.357 + 1G \> A (IVS6 + 1G \> A) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forward sequence analysis of exon 6 and adjacent intronic sequence of the *PAX6* gene in patient p5. The *arrow* indicates the heterozygous G/A transition in intron 6 at position +1 c.357 + 1G \> A

Sequencing of the *PAX6* gene promoter in patients p2, p3, and p6 did not identify any mutation in this region. So, the molecular methods used in this study did not allow to detect any mutations in patients p2, p3, and p6. Therefore, array comparative genomic hybridization analysis of these three patients was performed. However, array comparative genomic hybridization (aCGH) analysis also did not reveal any causative mutation. The patients' molecular findings are summarized in Table [3](#Tab3){ref-type="table"}.Table 3Molecular analysis resultsPatientOccurrenceMLPA*PAX6* gene sequencing*PAX6* gene promoter sequencingp1FNc.718C \> T--p2FNNNp3SNNNp4SNc.949C \> T--p5SNc.357 + 1G \> A--p6No dataNNNp7FNc.949C \> T--p8SHeterozygous deletion: *PAX6*, *DCDC1*, *ELP4*, *BDNF*, *FSHB*N--p9SHeterozygous deletion: *PAX6*, *DCDC1*, *ELP4*, *FSHB*, *RCN1*, *DKFZp686k1684*N--p10FHeterozygous deletion: *DCDC1*, *DPH4*, *IMMP1L*, *ELP4*N--p11SHeterozygous deletion of the 11p13 region (including *WT1*)N--p12FHeterozygous deletion: exons 1--8 of *PAX6*N--*F* familial, *S* sporadic, *N* normal sequence

Discussion {#Sec8}
==========

This is the first molecular study carried out on Polish patients with aniridia. In this study, we identified the alterations that cause the disease in 9 of 12 examined (75 %) patients with aniridia. The major finding of the present study is the great diversity of the molecular basis of aniridia in Polish patients. It is also worth mentioning that, in our group of patients, aniridia is more frequently caused by large deletions than by the *PAX6* gene point mutations. This statement is in contrast to larger studies done by Ton et al. ([@CR14]), Kokotas and Petersen ([@CR9]), and Park et al. ([@CR12]). Those researchers stated that heterozygous mutations in the *PAX6* gene are found in about 40--80 % of all non-syndromic aniridia patients. However, we must remember that our results are based on a small group, thus, our conclusion requires further verification with a larger cohort of aniridia patients.

The large deletion containing not only *PAX6* but also several other genes and the *RCN1* gene was detected by MLPA analysis in patient p9 (Table [3](#Tab3){ref-type="table"}). The *RCN1* gene is a Ca^2+^ binding protein, participating in the secretory pathway. Favor et al. ([@CR5]) reported that mouse, containing a heterozygous deletion of the *AX6* and *RCN1* genes, presents an extreme microphthalmia. They suggest that *RCN1* may have an influence on the eye phenotype in *PAX6* contiguous gene deletions. A familial case of aniridia resulting from a deletion containing *PAX6*, *RCN1*, and *DKFZp686k1684* was reported by Zhang et al. ([@CR16]). Severe visual impairment observed in the described family is compatible with the mouse phenotype reported by Favor et al. ([@CR5]). Patient p9 contains a very similar deletion of the downstream flanking region of *PAX6* to the family described by Zhang et al. ([@CR16]). However, our patient exhibits no significant phenotype differences in comparison to other aniridia patients presented in this study. Microphthalmia was not observed.

When the deletion does not include the *PAX6* sequence, then the so-called "position effect" is the underlying pathogenic mechanism of aniridia in these patients. Such a case is observed in patient p10, who has been diagnosed to have aniridia, despite the fact that the structure of the *PAX6* gene was normal. Submicroscopic deletions not involving the *PAX6* gene in the patients with aniridia were previously described by several authors (Lauderdale et al. [@CR10]; D'Elia et al. [@CR3]; Davis et al. [@CR2]; Wawrocka et al. [@CR15]). MLPA analysis revealed in this patient a heterozygous deletion encompassing several genes, including the *ELP4* gene. Kleinjan et al. ([@CR8]) confirmed that cis-regulatory elements located within the introns of the *ELP4* gene are *PAX6*-specific long-range control elements, essential for normal expression of the gene. Functional studies in human cells and animal models confirmed the presence of 3′ regulatory elements in the downstream region of *PAX6*, which are essential for normal expression of the gene. Our molecular findings provide further evidence of the existence of the distant 3′ regulatory elements in the downstream region of the *PAX6* gene, which are known from other studies to influence the level of protein expression.

DNA sequencing of the *PAX6* gene revealed three different mutations: two nonsense mutations, c.718C \> T and c.949C \> T (in two patients), and one splice-site mutation, c.357 + 1G \> A. It was previously described that the mutation c.357 + 1G \> A lead to the use of a cryptic splice donor site within exon 6, leading to an in-frame deletion of 36 amino acids from the PD (Hingorani et al. [@CR7]). The heterozygous mutation c.718C \> T (p.Arg240\*) in patient p1 occurred in the protein HD. In two unrelated patients (p4 and p7), identical heterozygous substitution c.949C \> T (p.Arg317\*) in the PST domain coding region was discovered. In accordance to the *PAX6* mutation database: c.718C \> T and c.949 C \> T are the most frequent *PAX6* mutations causing aniridia. Despite the presence of the same mutation, both patients represent quite divergent phenotypes. Singh et al. ([@CR13]) showed that the variable phenotype could be explained by differences in PAX6 protein levels, the ratio of mutant and normal protein, and interaction with different molecular factors. It was reported that mutations behind the HD could lead to more severe phenotypes in comparison with truncating mutations in the PD or HD domains (Kokotas and Petersen [@CR9]; Park et al. [@CR12]). This partly agrees with our observations that patient p4 (mutation in the PST domain) showed a more severe phenotype of aniridia in comparison to patient p1 (mutation in the HD) (Table [1](#Tab1){ref-type="table"}).

We have not determined any genetic causes of aniridia in three patients (p2, p3, and p6). The disease can be caused by abnormalities in the *PAX6* gene promoter or in the regulatory elements that affect the normal expression of the gene but are not routinely subjected to sequencing. Therefore, we decided to sequence the *PAX6* gene promoter in these patients. However, the sequencing did not reveal any mutation in the *PAX6* promoter. Another possible explanation for this fact is that chromosomal rearrangements that involved a gene or genes in the 11p13 region do not include the probes used in the MLPA analyses. Patient p2 suffers from aniridia and microphthalmia. The presence of microphthalmia with aniridia suggests the possibility of genocopy. Therefore, another gene involved in oculogenesis can be responsible for the disease. Possibly, the damage of the iris only resembles aniridia. aCGH analysis of patient p2 was performed, as well as in two other patients, in whom the genetic background of aniridia was not determined (p3, p6). This analysis allows to uncover smaller, rare CNVs that cannot be detected by lower resolution molecular techniques. However, no causative mutation was found.

Ophthalmic findings revealed nearly no phenotypic variabilities of the aniridia. Patients having deletion 3′ to the *PAX6* gene exhibit no significant phenotypic differences compared to the patients with point mutations in the *PAX6* gene. Due to quite the homogenous clinical symptoms and a small number of patients, we were not able to define any genotype--phenotype correlations. The findings of the current study are consistent with those of D'Elia et al. ([@CR3]), Lim et al. ([@CR11]), and Park et al. ([@CR12]), who did not find any phenotypic differences according to the identified genotype. Defining the genotype--phenotype correlation requires the analysis of a larger cohort of patients.

In connection to the great variability of mutations in aniridia patients, it is recommended to perform several analyses to detect the genetic background of aniridia. First of all, we care about the exclusion of life-threatening Wilms' tumor (associated with the *WT1* gene deletion) and then the detection of genetic causes of aniridia. Therefore, we decided to perform MLPA analysis first (to detect structural rearrangements in the *PAX6* gene and 11p13 region) and then *PAX6* gene sequencing (to identify point mutations). Additionally, gene sequencing is not usually used to detect copy number changes; therefore, in our opinion, it is better to begin the molecular analysis with MLPA or aCGH.
